A similar effect was observed after the administration of 0.8 μM GSK101 [Figures 4A,B,E; Supplementary Figure S3C], a potent agonist of the mechanosensory channel Trpv4 (Thorneloe et al., 2008) with a demonstrated cardioprotective effect when administered after acute myocardial infarction in rats (Yang et al., 2023). Here, TRPV4 is linked to myocardial infarction.